2024
Ptcog International Survey of Practice Patterns and Trends in Utilization of Proton Therapy for Breast Cancer
Choi I, Abeloos C, Lozano A, Kim M, Hanlon A, Vargas C, Maduro J, Bradley J, Offersen B, Haffty B, Pankuch M, Amos R, Kim N, Kirova Y, Mutter R. Ptcog International Survey of Practice Patterns and Trends in Utilization of Proton Therapy for Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e742-e743. DOI: 10.1016/j.ijrobp.2024.07.1632.Peer-Reviewed Original ResearchRegional nodal irradiationParticle Therapy Co-Operative GroupBreast cancerBC patientsPractice patternsDose-fractionation regimensHighly-selected patientsProton beam therapyPatient selection criteriaPencil beam scanningFisher's exact testEvolution of practice patternsPatient selection methodsClinical trial enrollmentSurvey of practice patternsImage guidance capabilitiesTreated BC patientsHypofractionated regimensNodal irradiationRecurrent BCBeam therapyPatient selectionProton therapyU.S. centersExact testA Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)
Poppe M, Le-Rademacher J, Haffty B, Hansen E, Agarwal J, Wagner J, Kong I, Armer J, Arthur D, Whelan T, Lee M, Kour O, Lustberg M, Partridge A, Carey L, Ruddy K, Gaffney D, Stecklein S, Bernstein M, Khan A. A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s11. DOI: 10.1016/j.ijrobp.2024.07.002.Peer-Reviewed Original ResearchPost-mastectomy radiation therapyNeoadjuvant chemotherapyBreast reconstructionComplication rateReconstruction complicationsBreast cancerNon-inferiorityHigh-risk breast cancerBody mass index >Conventionally fractionated radiationGenetic predisposition genesImplant-only reconstructionsMedian follow-upImmediate breast reconstructionOne-sided type I errorNon-inferiority marginStandard of careHypofractionated radiationRegional recurrenceRadiation therapyTumor characteristicsInvasive BCAdjuvant chemotherapyPredisposition genesMedian ageFirst Results of the Primary Outcome of a Phase II Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Breast Cancer Patients
Yehia Z, Sherwani Z, Chakraborty M, Ohri N, Grann A, Eladoumikdachi F, Kowzun M, Kumar S, Potdevin L, Blackwood M, Toppmeyer D, Haffty B. First Results of the Primary Outcome of a Phase II Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Breast Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2024 PMID: 39241809, DOI: 10.1016/j.ijrobp.2024.08.043.Peer-Reviewed Original ResearchWhole breast RTBreast-conserving therapyBoost volumePostoperative RTRT boostPrimary outcomeBreast RTRadiation therapyCosmetic outcomeWound complicationsBreast cancerClinically node-negative breast cancerPhase II prospective clinical trialMedian clinical tumor sizePostoperative whole-breast RTProspective phase 2 trialIncidence of grade 3Node-negative breast cancerProspective phase 2 studyRate of postoperative wound complicationsDuctal carcinoma in situClinical tumor sizeCarcinoma in situPhase 2 studyPhase 2 trialPTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer
Choi J, Hardy-Abeloos C, Lozano A, Hanlon A, Vargas C, Maduro J, Bradley J, Offersen B, Haffty B, Pankuch M, Amos R, Kim N, MacDonald S, Kirova Y, Mutter R. PTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer. Clinical And Translational Radiation Oncology 2024, 48: 100847. PMID: 39280125, PMCID: PMC11399555, DOI: 10.1016/j.ctro.2024.100847.Peer-Reviewed Original ResearchProton beam therapyBreast cancer patientsParticle Therapy Co-Operative GroupPatient selection methodsBreast cancerCancer patientsTreat breast cancer patientsRegional nodal irradiationFisher's exact testSurvey of practice patternsModerate hypofractionationNodal irradiationRadiation oncologistsBeam therapyPBT patientsProton therapyExact testU.S. centersDescriptive statisticsEuropean centersPractice patternsPatientsResponding centersBreastAsian centersRadiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives
Kim J, Fahmy V, Haffty B. Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives. Expert Review Of Anticancer Therapy 2024, 24: 211-217. PMID: 38502143, DOI: 10.1080/14737140.2024.2333320.Peer-Reviewed Original ResearchTriple-negative breast cancerPoly (ADP-ribose) polymeraseLocoregional controlRadiation therapyBreast cancerImpact of post-mastectomy radiation therapyPost-mastectomy radiation therapyEffects of radiotherapySynergistic effects of radiotherapyPersonalized treatment approachesImproved survival ratesIntegration of radiomicsImmunotherapy combinationsBRCA1/2 mutationsRadiotherapy responseOvercome radioresistanceTargeted radiosensitizationImprove patient outcomesRadiosensitizing strategiesNovel radiosensitizersTarget biological pathwaysTreatment strategiesTreatment outcomesMolecular profilingRadiotherapy
2023
Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA
Jagsi R, Griffith K, Harris E, Wright J, Recht A, Taghian A, Lee L, Moran M, Small W, Johnstone C, Rahimi A, Freedman G, Muzaffar M, Haffty B, Horst K, Powell S, Sharp J, Sabel M, Schott A, El-Tamer M. Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA. Journal Of Clinical Oncology 2023, 42: 390-398. PMID: 38060195, DOI: 10.1200/jco.23.02270.Peer-Reviewed Original ResearchBreast-conserving surgeryIpsilateral breast eventsEndocrine therapyPostmenopausal patientsBreast cancerCrude rateLower riskBreast cancer-specific survival ratesUnifocal invasive breast cancersYears of ETCancer-specific survival ratesStage I breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Omission of radiotherapyYounger postmenopausal patientsPatients age 50Primary end pointBreast conserving surgeryGrowth factor receptor 2I breast cancerInvasive breast cancerRecurrence 5 yearsPatients age 65Single-arm trial